Compare ESQ & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | MLYS |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.2M | 3.1B |
| IPO Year | 2017 | 2023 |
| Metric | ESQ | MLYS |
|---|---|---|
| Price | $107.21 | $36.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $113.00 | $46.40 |
| AVG Volume (30 Days) | 72.0K | ★ 1.7M |
| Earning Date | 01-22-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 14.70 | N/A |
| EPS | ★ 5.68 | N/A |
| Revenue | ★ $131,743,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.55 | N/A |
| P/E Ratio | $18.88 | ★ N/A |
| Revenue Growth | ★ 13.37 | N/A |
| 52 Week Low | $68.90 | $8.24 |
| 52 Week High | $108.55 | $47.65 |
| Indicator | ESQ | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 67.82 | 40.09 |
| Support Level | $100.63 | $35.77 |
| Resistance Level | $108.55 | $44.13 |
| Average True Range (ATR) | 2.74 | 1.93 |
| MACD | 0.58 | -0.64 |
| Stochastic Oscillator | 87.64 | 14.95 |
Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.